Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (6), the stock would be worth ₩4 895.58 (22% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.7 | ₩6 280 |
0%
|
| 3-Year Average | 6 | ₩4 895.58 |
-22%
|
| 5-Year Average | 8.2 | ₩6 634.64 |
+6%
|
| Industry Average | 23.2 | ₩18 861.14 |
+200%
|
| Country Average | 15.1 | ₩12 225.61 |
+95%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
S
|
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
|
72.6B KRW | 7.7 | 6.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
910.2B USD | 67.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.2B USD | 19.3 | 16.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.1 |
| Median | 15.1 |
| 70th Percentile | 28.4 |
| Max | 21 200 |
Other Multiples
Sinil Pharmaceutical Co Ltd
Glance View
Sinil Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Chungju, Chungcheongbuk-Do. The Company’s products consist of antihyperlipidemic agents, antitussives, expectorants, anti-antipyretic agents, analgesic agents, inflammatory agents, dermatological treatments, chemotherapeutic agents, antihistamines, antihypertensives and mixed vitamins, among others. The company also engages in the leasing of real estate.
